Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Bispecific gp100 × CD3 (ImmTAC)

Tebentafusp (Specialist drug)

Brand names: Kimmtrak

Tebentafusp is a bispecific T-cell engager used in HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It combines an affinity-enhanced T-cell receptor that recognises a gp100 peptide presented on HLA-A*02:01 with an anti-CD3 effector, redirecting T cells to kill gp100-expressing uveal melanoma cells.

Prescribing in practice

  • Eligibility requires HLA-A*02:01 positivity, and cytokine release syndrome is common, so the first infusions are given with a step-up schedule under monitoring in a setting able to manage acute reactions.
  • Skin reactions related to gp100 expression in melanocytes are frequent.
  • Given by intravenous infusion by specialists with monitoring for hypotension and other features of cytokine release.

Monitoring

Monitor for cytokine release syndrome (including blood pressure) during and after early infusions and for skin reactions.

Counselling the patient

  • Report fever, rash, dizziness, or feeling faint during or after infusions.
  • Expect skin changes such as rash, itching or swelling, particularly early in treatment.
  • Attend the extended monitoring after your first infusions as arranged.

Evidence & guidelines

A randomised phase 3 trial demonstrated an overall survival benefit in metastatic uveal melanoma, supporting its approval.

Reference: NICE TA864; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways